| Literature DB >> 33663045 |
He Jien1, Li Xiaohua2.
Abstract
BACKGROUND: The aim of this study was to systematically evaluate and compare the effectiveness and safety of laparoscopic versus open resection (LR vs OR) in the treatment of hepatic hemangioma.Entities:
Mesh:
Year: 2021 PMID: 33663045 PMCID: PMC7909164 DOI: 10.1097/MD.0000000000024155
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Risk of bias of RCTs: “+” indicated a “low” risk of bias; “?” indicated an “unclear” risk of bias.
The characteristics of all the included RCTs.
| Author | Year | Type | Group | N | Gender (M/F) | Age (yr) | Size (cm) | Tumor location (Couinaud segmentation) (case) |
| Huang et al[ | 2018 | RCT | LR | 30 | 17/13 | 51.07 ± 3.92 | 5.13 ± 1.24 | II + III (7), IV + V (13), VI + VII (10) |
| OR | 30 | 16/14 | 50.79 ± 4.05 | 5.28 ± 1.17 | II + III (5), IV + V (14), VI + VII (11) | |||
| Zhang et al[ | 2018 | RCT | LR | 30 | 17/13 | 41.7 ± 3.8 | 4.75 ± 1.39 | II + III (7), IV (13), V (10), VI (10) |
| OR | 30 | 16/14 | 42.6 ± 4.0 | 4.83 ± 1.15 | II + III (6), IV (8), V (8), VI (8) | |||
| Li et al[ | 2018 | RCT | LR | 9 | 3/6 | 55.7 ± 2.8 | – | – |
| OR | 9 | 4/5 | 53.8 ± 3.5 | – | – | |||
| Wang et al[ | 2017 | RCT | LR | 30 | 6/24 | 41.67 ± 2.48 | 11.51 ± 0.29 | II + III (6), III + IV (6), V (8), VI + VII (5), VIII (5) |
| OR | 30 | 7/23 | 41.13 ± 2.46 | 11.24 ± 0.42 | II + III (6), III + IV (6), V (8), VI + VII (5), VIII (5) | |||
| Liu et al[ | 2016 | RCT | LR | 29 | 13/16 | 42.5 ± 1.45 | 7.35 ± 2.74 | II (12), VII (11), VIII (6) |
| OR | 29 | 17/12 | 43.2 ± 2.36 | 7.58 ± 2.28 | II (10), VII (14), VIII (5) | |||
| Fu et al[ | 2016 | RCT | LR | 37 | 21/16 | 48.3 ± 12.2 | 5.68 ± 0.71 | I (3), IV (7), VII (11), VIII (10), IV + VIII (4), VII + VIII (2) |
| OR | 37 | 19/18 | 47.1 ± 11.3 | 5.53 ± 0.82 | I (4), IV (7), VII (9), VIII (6), IV + VIII (5), VII + VIII (6) | |||
| Zhang et al[ | 2016 | RCT | LR | 12 | 7/5 | 56 (41–60) | 5.32 ± 1.75 | VII (12) |
| OR | 12 | 8/4 | 54 (43–59) | 5.55 ± 1.99 | VII (12) | |||
| Liu et al[ | 2016 | RCT | LR | 29 | 11/18 | 37.45 ± 3.94 | 7.26 ± 1.02 | II + III (5), IV (8), V + VIII (8), VI + VII (8) |
| OR | 27 | 11/16 | 37.46 ± 3.54 | 5.68 ± 0.57 | II + III (6), IV (7), V + VIII (7), VI + VII (7) | |||
| Lin et al[ | 2016 | RCT | LR | 28 | 12/16 | 49.4 ± 8.5 | 5.03 ± 1.11 | V (6), VI (13), V + VI (9) |
| OR | 28 | 13/15 | 49.1 ± 8.1 | 5.18 ± 1.04 | V (8), VI (12), V + VI (8) | |||
| Jiang et al[ | 2016 | RCT | LR | 25 | 6/19 | 47.62 ± 7.13 | 9.58 ± 2.43 | – |
| OR | 25 | 5/20 | 47.61 ± 7.36 | 9.67 ± 2.31 | – | |||
| Zou et al[ | 2013 | RCT | LR | 15 | 5/10 | 38.1 ± 1.2 | 5.12 ± 0.56 | V + VI (6), VII + VIII (9) |
| OR | 15 | 5/10 | 41.1 ± 1.4 | 6.12 ± 0.56 | V + VI (8), VII + VIII (7) | |||
| Gao et al[ | 2012 | RCT | LR | 20 | 6/14 | 37–43.5 | 5.2 ± 0.6 | II + III (4), V + VI (7), VII + VIII (9) |
| OR | 28 | 8/20 | 37.5–48 | 6.1 ± 0.6 | II + III (7), V + VI (12), VII + VIII (9) |
LR = laparoscopic resection, OR = open resection, RCTs = randomized clinical trials.
The characteristics of all the included OCSs.
| Author | Year | Type | Group | N | Gender (M/F) | Age (yr) | Size (cm) | Tumor location (Couinaud segmentation) (case) |
| Fan et al[ | 2018 | OCS | LR | 20 | 7/13 | 47.8 ± 8.2 | 13.2 + 2.9 | II + III (5), IV (4), V + VIII (3), VI + VII (8) |
| OR | 42 | 7/35 | 45.2 ± 6.1 | 14.9 + 5.3 | II + III (13), IV (4), V + VIII (12), VI + VII (13) | |||
| Ji et al[ | 2018 | OCS | LR | 32 | 14/18 | 43.5 (27–65) | 6.26 ± 1.54 | III (5), II + III (10), II + III + IV (8), V + VI (6), VII + VIII (3) |
| OR | 35 | 15/20 | 47.7 (19–67) | 6.15 ± 1.73 | II + III (3), II + III + IV (9), VI + VII (7), VII + VIII (7), VI + VII + VIII (6), V + VI + VII + VIII (3) | |||
| Cheng et al[ | 2018 | OCS | LR | 7 | 2/5 | 48.4 ± 10.8 | 5.49 ± 1.46 | II (2), III (3), II + III (2) |
| OR | 7 | 1/6 | 42.43 ± 8.4 | 5.53 ± 2.01 | II (3), III (3), II + III (1) | |||
| Chen et al[ | 2018 | OCS | LR | 46 | 17/29 | 53.8 ± 7.1 | 5.7 ± 1.4 | II + III (35), IV (11) |
| OR | 61 | 21/40 | 55.1 ± 10.5 | 6.1 ± 1.7 | II + III (41), IV (20) | |||
| Qian et al[ | 2017 | OCS | LR | 50 | 28/22 | 45.26 ± 8.36 | 7.26 ± 1.18 | II (14), III (8), V + VI (12), VII + VIII (16) |
| OR | 50 | 29/21 | 45.32 ± 8.42 | 7.28 ± 1.19 | II (11), III (13), V + VI (14), VII + VIII (12) | |||
| Liu[ | 2017 | OCS | LR | 23 | 14/9 | 42.54 ± 0.58 | 7.26 ± 1.02 | II + III + IV (11), V + VI + VII + VIII (12) |
| OR | 23 | 13/10 | 45.74 ± 1.04 | 5.68 ± 0.57 | II + III + IV (9), V + VI + VII + VIII (14) | |||
| Fang et al[ | 2017 | OCS | LR | 26 | 16/10 | 45.8 ± 4.7 | 4.9 ± 1.1 | II + III (2), IV (9), V–VIII (16) |
| OR | 20 | 11/9 | 42.4 ± 5.4 | 5.1 ± 0.9 | II + III (1), IV (7), V–VIII (12) | |||
| Zhang et al[ | 2016 | OCS | LR | 23 | 12/11 | 40.29 ± 3.31 | 6.35 ± 2.58 | II (4), III + IV + V (9), VI + VII (4), VIII (6) |
| OR | 23 | 13/10 | 40.23 ± 3.24 | 6.18 ± 2.29 | II (5), III + IV + V (10), VI + VII (4), VIII (4) | |||
| Li et al[ | 2016 | OCS | LR | 35 | 21/14 | 41.8 ± 7.6 | 6.5 ± 1.3 | II + III (7), IV (5), V (6), VI + VII (9), VIII (8) |
| OR | 35 | 19/16 | 42.5 ± 6.9 | 6.2 ± 1.5 | II + III (8), IV (6), V (7), VI + VII (8), VIII (6) | |||
| Yu and Yu[ | 2015 | OCS | LR | 31 | 15/16 | 48.6 ± 12.2 | – | – |
| OR | 100 | 35/65 | 48.4 ± 9.5 | – | – | |||
| Fan and Zhou[ | 2012 | OCS | LR | 19 | 7/12 | 37–59 | 7.03 ± 2.86 | II (8), III (6), II + III (5) |
| OR | 27 | 10/17 | 36–60 | 7.27 ± 2.99 | II (11), III (9), II + III (7) | |||
| Hu et al[ | 2008 | OCS | LR | 14 | 4/10 | 37.5 ± 7.8 | 5.2 ± 0.6 | II (4), III (6), II + III (4) |
| OR | 24 | 7/17 | 40.4 ± 8.3 | 6.1 ± 0.6 | II (7), III (12), II + III (5) |
LR = laparoscopic resection, OCSs = observational clinical studies, OR = open resection.
Jadad scale system for RCTs.
| Refs | Randomization | Concealment of allocation | Double blinding | Withdrawals and drop out | Total score |
| Huang et al[ | 2 | 2 | 1 | 1 | 6 |
| Zhang et al[ | 2 | 2 | 1 | 0 | 6 |
| Li et al[ | 2 | 2 | 1 | 0 | 5 |
| Wang et al[ | 2 | 2 | 0 | 0 | 4 |
| Liu et al[ | 2 | 2 | 1 | 1 | 6 |
| Fu et al[ | 2 | 2 | 1 | 0 | 5 |
| Zhang et al[ | 2 | 2 | 1 | 0 | 5 |
| Liu et al[ | 2 | 2 | 1 | 0 | 5 |
| Lin et al[ | 2 | 2 | 1 | 1 | 6 |
| Jiang et al[ | 2 | 2 | 0 | 0 | 4 |
| Zou et al[ | 2 | 2 | 1 | 0 | 5 |
| Gao et al[ | 2 | 2 | 0 | 0 | 4 |
The quality of the RCT studies was evaluated using the Jadad scale. The system was used to assess randomization, concealment of allocation, blinding, and withdrawals in the study. Each item was given a score of 0–2 and 7 score in total. If the total score was ≥4, the RCT was of high quality.
Quality assessment for OCSs using MINORS.
| Refs | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | (10) | (11) | (12) | Total score |
| Fan et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Ji et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Cheng et al[ | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 22 |
| Chen et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Qian et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Liu[ | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 21 |
| Fang et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 2 | 19 |
| Zhang et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Li et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Yu and Yu[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
| Fan and Zhou[ | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 22 |
| Hu et al[ | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 20 |
MINORS criteria include the following items: (1): A stated aim of the study; (2): Inclusion of consecutive patients; (3): Prospective collection of data; (4): Endpoint appropriate to the study aim; (5): Unbiased evaluation of endpoints; (6): Follow-up period appropriate to the major endpoint; (7): Loss to follow-up not exceeding 5%; (8): A control group having the gold standard intervention; (9): Contemporary groups; (10): Baseline equivalence of groups; (11): Prospective calculation of the sample size; (12): Statistical analyses adapted to the study design. Items are scored as follows: 0 (not reported); 1 (reported but inadequate); or 2 (reported and adequate). The ideal global score for comparative studies is 24.
Figure 2Meta-analysis of the operation time.
Figure 3Meta-analysis of the intraoperative blood loss.
Figure 4Meta-analysis of the hepatectomy time.
Figure 5Meta-analysis of the postoperative exhaust time.
Figure 6Meta-analysis of the postoperative complications.
Figure 7Meta-analysis of the postoperative biliary fistula.
Figure 8Meta-analysis of the postoperative intra-abdominal hemorrhage.
Figure 9Meta-analysis of the postoperative intra-abdominal infection.
Figure 10Meta-analysis of the postoperative ALT values.
Figure 13Meta-analysis of the postoperative ALB values.
Figure 14Meta-analysis of the postoperative VAS score.
Figure 15Meta-analysis of the postoperative hospitalize length.
Figure 16Meta-analysis of the hospitalized cost.
Figure 17Meta-analysis of the postoperative hemangioma recurrence.
Figure 18Funnel plots were created to assess the publication bias in our meta-analysis. A = operation time B = intraoperative blood loss, C = hepatectomy time, D = exhaust time, E = postoperative complications, F = bile leak, G = postoperative intra-abdominal hemorrhage, H = postoperative intra-abdominal infection, I = ALT, J = AST, K = TBil, L = ALB, M = VAS score, N = postoperative hospitalize length, O = hospitalized cost, P = postoperative hemangioma recurrence.